I have created this chart to visually represent the universal role Bisantrene plays in cardioprotection against common cardiotoxic chemotherapies. A 1 uM dose of Bisantrene significantly improves HCM viability (p < 0.001). The real value for this opportunity is that while providing cardioprotection, Bisantrene improves cancer cell killing in combination with these chemotherapies. There are already 2 clinical trials where Bisantrene is used in combination with moderately cardiotoxic chemotherapies not listed in the figure below that achieved combined ORR of 46% and 40% with no clinically relevant signs of cardiotoxicity.
A drug with a universal cardioprotection mechanism combined with a universal cytotoxicity mechanism has not existed until now.
Cardioprotection thread, page-518
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
-0.063(3.70%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.66 | $1.57 | $266.8K | 163.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 574 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.63 | 6622 | 1 |
View Market Depth
| Last trade - 14.37pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |